HRC Ledger
Opportunity

Purchase of Rapid Syndromic Molecular Testing Reagents for Seattle VAMC

Response due

September 10, 2026

Agency
260-NETWORK Contract Office 20 (36C260)
Estimated value
Not stated
Our scope is to acquire specific FDA-approved infectious disease and oncology assays formulated as single-use test cartridges and reagents that are equal to and/or compatible to what is currently being used on the VA owned instrument/analyzer. Required rapid molecular assays include targets for C. difficile, SARS-CoV-2 with Influenza A & B and RSV, Strep A, MTB IVD – Mycobacterium tuberculosis with Rif, MVP-Multiplex Vaginal Panel, GI Panel, MRSA Carba-R, Norovirus, BCR-ABL, FII & FV and vanA PCR. The kit storage temperature should be 2 – 28°C and not require refrigeration. Time and date of delivery to be determined by the PSHCS Microbiology Department.

Key dates

Posted
August 19, 2026
Response due
September 10, 2026

Organization

NETWORK CONTRACT OFFICE 20

Buying history

  • Records267 total
  • Opportunities / awards14 / 117
  • Value range$1,164 – $9,500,000
  • ActiveApril 28, 2026 – October 26, 2026

What they buy

  • Clinical (200)
  • Administrative (67)

Set-asides used

  • Small Business Set Aside - Total (55)
  • No Set aside used (38)
  • SDVOSB Set-Aside (FAR 19.14) (13)
  • VOSB Set-Aside (VA) (1)

Who holds their work today

  1. OREGON HEALTH & SCIENCE UNIVERSITY8 wins · $18,293,697 · last March 1, 2026
  2. QUEST DIAGNOSTICS INCORPORATED8 wins · $9,126,669 · last March 1, 2026
  3. LABORATORY CORPORATION OF AMERICA9 wins · $5,408,728 · last March 1, 2026
  4. V.M.C., INC.1 win · $5,033,114 · last May 1, 2023
  5. STG INTERNATIONAL, INC.2 wins · $3,624,232 · last April 1, 2026

Also open from this buyer

Ways to meet this buyer

Upcoming

View source document →

Source link on sam.gov.

Source record

Buyer type
Federal
Jurisdiction
Federal (US)
Category
Clinical
Set-aside
No Set aside used
NAICS
325413
PSC
6515